NASDAQ:FGEN

FibroGen (FGEN) Stock Forecast, Price & News

$0.97

+0.01 (+1.04%)

(As of 09/28/2023 ET)

Compare

Today's Range: $0.90
▼
$1.00
50-Day Range: $0.79
▼
$2.22
52-Week Range: $0.70
▼
$25.69

Volume: 4.62 million shs
Average Volume: 6.29 million shs
Market Capitalization: $95.42 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $22.00

FibroGen MarketRank™ Forecast

Analyst Rating: Reduce
1.67 Rating Score
Upside/Downside: 2,164.3% Upside
$22.00 Price Target
Short Interest: Bearish
11.96% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.84
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$16,524 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.47) to ($0.80) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

442nd out of 970 stocks

Pharmaceutical Preparations Industry

196th out of 455 stocks

2.8

Analyst's Opinion

Consensus Rating
FibroGen has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no buy ratings, 4 hold ratings, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $22.00, FibroGen has a forecasted upside of 2,164.3% from its current price of $0.97.
Amount of Analyst Coverage
FibroGen has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
11.96% of the float of FibroGen has been sold short.
Short Interest Ratio / Days to Cover
FibroGen has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in FibroGen has recently increased by 0.46%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
FibroGen does not currently pay a dividend.
Dividend Growth
FibroGen does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
FibroGen has received a 74.19% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for the autoimmune system", "Clinical research services for cancer", and "Clinical research services for deficiency diseases" products. See details.
Environmental Sustainability
The Environmental Impact score for FibroGen is -0.84.

2.9

News and Social Media Coverage

News Sentiment
FibroGen has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for FibroGen this week, compared to 2 articles on an average week.
Search Interest
Only 6 people have searched for FGEN on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.
MarketBeat Follows
6 people have added FibroGen to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, FibroGen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,524.00 in company stock.
Percentage Held by Insiders
Only 2.39% of the stock of FibroGen is held by insiders.
Percentage Held by Institutions
78.34% of the stock of FibroGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for FibroGen are expected to grow in the coming year, from ($2.47) to ($0.80) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of FibroGen is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of FibroGen is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About FibroGen (NASDAQ:FGEN) Stock

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

FGEN Price History

30 days | 90 days | 365 days | Advanced Chart

FGEN Stock News Headlines

August 30, 2023 | markets.businessinsider.com

FibroGen's Pamrevlumab Doesn't Meet Goals In Phase III LELANTOS-2 Trial; Stock Down In Pre-market

August 30, 2023 | markets.businessinsider.com

Three In A Row: FibroGen's Investigational Drug Flunks In Another Study For Rare Disease In Young Boys

September 29, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

August 30, 2023 | proactiveinvestors.com

FibroGen stock plummets as muscular dystrophy drug trial fails

August 30, 2023 | msn.com

FibroGen (NASDAQ: FGEN) Tumbles after Setback in Phase 3 DMD Trial

August 29, 2023 | marketwatch.com

Stocks to Watch: FibroGen, Box

August 29, 2023 | finance.yahoo.com

FibroGen's drug misses mark on yet another clinical trial

August 29, 2023 | marketwatch.com

FibroGen Shares Sink 16% on Pamrevlumab Study Not Meeting Primary Endpoint

September 29, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

August 29, 2023 | msn.com

FibroGen stock tumbles on failed Phase 3 study for muscular dystrophy drug

August 29, 2023 | finance.yahoo.com

FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy

August 16, 2023 | finance.yahoo.com

Down -46.88% in 4 Weeks, Here's Why FibroGen (FGEN) Looks Ripe for a Turnaround

August 9, 2023 | finance.yahoo.com

Is There An Opportunity With FibroGen, Inc.'s (NASDAQ:FGEN) 42% Undervaluation?

August 9, 2023 | finance.yahoo.com

FibroGen Reports Second Quarter 2023 Financial Results

August 8, 2023 | msn.com

B of A Securities Downgrades FibroGen (FGEN)

August 8, 2023 | markets.businessinsider.com

Expert Ratings for FibroGen

August 8, 2023 | seekingalpha.com

FibroGen Q2 2023 Earnings Preview

August 8, 2023 | finance.yahoo.com

FibroGen (FGEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

August 8, 2023 | finance.yahoo.com

FibroGen, Inc. (NASDAQ:FGEN) Q2 2023 Earnings Call Transcript

July 31, 2023 | bizjournals.com

San FranciscoBusiness Times

July 25, 2023 | finance.yahoo.com

FibroGen CEO resigns after back-to-back drug study failures, job cuts

July 25, 2023 | finanznachrichten.de

FibroGen, Inc.: FibroGen Announces Leadership Transition

July 25, 2023 | finance.yahoo.com

FibroGen Announces Leadership Transition

July 24, 2023 | finance.yahoo.com

FibroGen to Report Second Quarter 2023 Financial Results

July 20, 2023 | msn.com

SF biotech company FibroGen laying off nearly a third of its workers

July 19, 2023 | bizjournals.com

Pioneering Mission Bay biotech company Fibrogen to cut more than 100 jobs

July 14, 2023 | finance.yahoo.com

FibroGen (FGEN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

See More Headlines

Receive FGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for FibroGen and its competitors with MarketBeat's FREE daily newsletter.

FGEN Company Calendar

Last Earnings: 8/07/2023
Today: 9/29/2023
Next Earnings (Estimated): 11/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:FGEN
CUSIP: N/A
CIK: 921299
Web: www.fibrogen.com
Phone: (415) 978-1200
Fax: 415-978-1902
Employees: 592
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $22.00
High Stock Price Forecast: $35.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +2,164.3%
Consensus Rating: Reduce
Rating Score (0-4): 1.67
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.39)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-293,650,000.00
Net Margins: -246.75%
Pretax Margin: -248.26%
Return on Equity: -879.75%
Return on Assets: -52.38%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.12
Quick Ratio: 1.91

Sales & Book Value

Annual Sales: $140.73 million
Price / Sales: 0.68
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.02) per share
Price / Book: -48.58

Miscellaneous

Outstanding Shares: 98,210,000
Free Float: 95,863,000
Market Cap: $95.42 million
Optionable: Optionable
Beta: 0.55

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Thane Wettig (Age 58)
Interim Chief Exec. Officer
Comp: $807.35k

Mr. Juan Graham (Age 46)
Sr. VP & CFO
Comp: $991.76k

Dr. Elias Kouchakji (Age 67)
Sr. VP of Clinical Devel., Drug Safety & Pharmacovigilance

Ms. Christine L. Chung (Age 55)
Sr. VP of China Operations
Comp: $1.27M

Dr. Barry A. Berkowitz Ph.D.
Founder

Dr. John J. Hunter Ph.D. (Age 60)
Chief Scientific Officer

Ms. Karen L. Bergman
VP of Investor Relations & Corp. Communications

Mr. Michael D. Lowenstein J.D.
Ph.D., Chief Legal Officer

Ms. Tricia Stewart
Chief People Officer

Mr. Kirk A. Christoffersen MBA (Age 54)
Chief Bus. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

FGEN Stock - Frequently Asked Questions

Should I buy or sell FibroGen stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 2 sell ratings and 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" FGEN shares.
View FGEN analyst ratings or view top-rated stocks.
What is FibroGen's stock price forecast for 2023?: 6 equities research analysts have issued 12-month price targets for FibroGen's shares. Their FGEN share price forecasts range from $2.00 to $35.00. On average, they anticipate the company's share price to reach $22.00 in the next year. This suggests a possible upside of 2,164.3% from the stock's current price.
View analysts price targets for FGEN or view top-rated stocks among Wall Street analysts.
How have FGEN shares performed in 2023?: FibroGen's stock was trading at $16.02 at the beginning of the year. Since then, FGEN stock has decreased by 93.9% and is now trading at $0.9716.
View the best growth stocks for 2023 here.
When is FibroGen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our FGEN earnings forecast.
How were FibroGen's earnings last quarter?: FibroGen, Inc. (NASDAQ:FGEN) released its earnings results on Monday, August, 7th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.07. The biopharmaceutical company had revenue of $44.32 million for the quarter, compared to analyst estimates of $34.17 million. FibroGen had a negative net margin of 246.75% and a negative trailing twelve-month return on equity of 879.75%.
What other stocks do shareholders of FibroGen own?: Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ).

When did FibroGen IPO?: (FGEN) raised $146 million in an initial public offering on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.
What is FibroGen's stock symbol?: FibroGen trades on the NASDAQ under the ticker symbol "FGEN."
How do I buy shares of FibroGen?: Shares of FGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is FibroGen's stock price today?: One share of FGEN stock can currently be purchased for approximately $0.97.
How much money does FibroGen make?: FibroGen (NASDAQ:FGEN) has a market capitalization of $95.42 million and generates $140.73 million in revenue each year. The biopharmaceutical company earns $-293,650,000.00 in net income (profit) each year or ($3.39) on an earnings per share basis.
How many employees does FibroGen have?: The company employs 592 workers across the globe.
How can I contact FibroGen?: FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The official website for the company is www.fibrogen.com. The biopharmaceutical company can be reached via phone at (415) 978-1200, via email at ir@fibrogen.com, or via fax at 415-978-1902.

This page (NASDAQ:FGEN) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial